Paloma Partners’s Cyclerion Therapeutics CYCN Stock Holding History

Paloma Partners’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-688	Closed	-$81K	–	2150
2020 Q2	$81K	Buy	+688	New	+$57.5K	﹤0.01%	1933

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's CYCN Position: Q3 2020 in Review

Paloma Partners sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 688 shares — an estimated $81K sold.

Paloma Partners first reported a position in CYCN in Q2 2020 and held it in 1 quarter. The position peaked at $81K in Q2 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

Paloma Partners reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 688 Cyclerion Therapeutics shares in Q3 2020, an estimated $81K.
Paloma Partners first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 1 quarter.
Paloma Partners's Cyclerion Therapeutics position peaked at $81K in Q2 2020.
73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.